USPTO serial 97647785
TCAR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MASON, JARED MICHAEL
- Law office
- TMO LAW OFFICE 119 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with TCAR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic proteins and therapeutic nucleic acids for human use for the treatment and prevention of cancer, infectious diseases, inflammation and inflammatory diseases; pharmaceutical preparations for human use, namely, biotherapeutics, medicines, and therapeutics, namely, pharmaceutical polypeptides, pharmaceutical T cell receptors, pharmaceutical nucleic acids, polypeptide-based therapeutics, cell-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics for the treatment and prevention of cancer, infectious diseases, inflammation and inflammatory diseases | ACTIVE | — |
| 042 | Scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, infectious diseases, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics; providing information on the subject of scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, infectious diseases, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 28, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 28, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 28, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 8, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 28, 2022 | NWAP | NEW APPLICATION ENTERED | — |